Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$221.38
+0.0%		$220.96
$18.51
▼
$221.42
$6.96B1.52928,762 shs2.69 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$150.37
-1.3%		$134.64
$77.58
▼
$156.92
$375.85B0.2111.02 million shs4.39 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
0.00%0.00%0.00%0.00%+249.01%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-1.28%+1.40%+17.17%+24.23%+78.57%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$221.38
+0.0%		$220.96
$18.51
▼
$221.42
$6.96B1.52928,762 shs2.69 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$150.37
-1.3%		$134.64
$77.58
▼
$156.92
$375.85B0.2111.02 million shs4.39 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
0.00%0.00%0.00%0.00%+249.01%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-1.28%+1.40%+17.17%+24.23%+78.57%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
2.30
Hold$169.88-23.27% Downside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.65
Moderate Buy$148.60-1.18% Downside

Current Analyst Ratings Breakdown

Latest MRK and CDTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/4/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$150.00 ➝ $170.00
8/25/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Hold (C)
8/25/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$155.00 ➝ $180.00
8/25/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Argus logo
Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$145.00 ➝ $170.00
8/21/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$140.00 ➝ $160.00
8/20/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$142.00 ➝ $170.00
8/20/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$145.00 ➝ $175.00
8/20/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperform ➝ Sector Perform$142.00 ➝ $150.00
8/20/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$116.00 ➝ $179.00
8/19/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/AN/AN/AN/A$14.92 per shareN/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$66.57B5.57$11.27 per share13.34$17.02 per share8.83
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$169.83M-$11.78N/AN/AN/AN/A-45.52%-38.31%N/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$18.25B$1.25120.3015.576.634.77%16.73%6.13%10/29/2026 (Estimated)

Latest MRK and CDTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2026Q2 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$0.26-$0.13+$0.13-$0.54$16.37 billion$16.61 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/AN/AN/AN/AN/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.402.26%+5.75%272.00%14 Years

Latest MRK and CDTX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/29/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.852.61%9/15/20269/15/202610/7/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/A
4.62
4.62
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1.22
1.32
1.10

Institutional Ownership

CompanyInstitutional Ownership
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
35.82%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%

Insider Ownership

CompanyInsider Ownership
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
3.89%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.17%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
9031.44 million30.22 millionNo Data
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.47 billion2.46 billionOptionable

Recent News About These Companies

Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know
 |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/merck-mrk-sees-more-significant-214502821.html
Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know
September 4 at 6:46 PM  |  zacks.comhttps://www.zacks.com/stock/news/2985485/merck-mrk-sees-a-more-significant-dip-than-broader-market-some-facts-to-know?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_6-2985485
Merck & Co., Inc. (NYSE:MRK) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says
September 4 at 10:35 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-merck-co-inc-nyse-mrk-stock-price-expected-to-rise-wells-fargo-company-analyst-says-2026-09-04/
Merck & Co., Inc. $MRK Shares Sold by TD Waterhouse Canada Inc.
September 4 at 5:52 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-merck-co-inc-mrk-shares-sold-by-td-waterhouse-canada-inc-2026-09-04/
NEOS Investment Management LLC Purchases 40,020 Shares of Merck & Co., Inc. $MRK
September 4 at 5:35 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-neos-investment-management-llc-purchases-40020-shares-of-merck-co-inc-mrk-2026-09-04/
Concurrent Investment Advisors LLC Has $36.09 Million Stock Position in Merck & Co., Inc. $MRK
September 4 at 4:07 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-concurrent-investment-advisors-llc-has-3609-million-stock-position-in-merck-co-inc-mrk-2026-09-04/
Burford Brothers Inc. Sells 7,962 Shares of Merck & Co., Inc. $MRK
September 4 at 4:07 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-burford-brothers-inc-sells-7962-shares-of-merck-co-inc-mrk-2026-09-04/
Merck's $8.4 Billion Keytruda Fortress Gets a 2028 Warning
September 3 at 8:50 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/mercks-8-4-billion-keytruda-212734101.html
Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug
September 3 at 3:50 PM  |  finance.yahoo.comhttps://finance.yahoo.com/m/3227a244-83a5-3806-82be-40cf153910a1/summit-therapeutics-says-it.html
Why Is Merck (MRK) Up 18.2% Since Last Earnings Report?
September 3 at 12:36 PM  |  zacks.comhttps://www.zacks.com/stock/news/2984565/why-is-merck-mrk-up-18-2-since-last-earnings-report?cid=cs-stocknewsapi-ft-realtime_blog-2984565
India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
September 3 at 12:00 PM  |  reuters.comhttps://www.reuters.com/legal/litigation/indias-cipla-chinas-qilu-partner-us-launch-mercks-keytruda-biosimilar-2026-09-03/
Nykredit A S Takes $100.08 Million Position in Merck & Co., Inc. $MRK
September 3 at 5:52 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nykredit-a-s-takes-10008-million-position-in-merck-co-inc-mrk-2026-09-03/
Merck & Co., Inc. $MRK Stock Holdings Decreased by Secure Asset Management LLC
September 3 at 5:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-merck-co-inc-mrk-stock-holdings-decreased-by-secure-asset-management-llc-2026-09-03/
Why Moderna's Cancer Vaccine Matters to Investors
September 2 at 12:04 PM  |  etftrends.comE
Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference
September 2 at 8:26 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/merck-participate-wells-fargo-21st-104500293.html
Nwam LLC Acquires 10,124 Shares of Merck & Co., Inc. $MRK
September 2 at 5:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nwam-llc-acquires-10124-shares-of-merck-co-inc-mrk-2026-09-02/
Northwestern Mutual Wealth Management Co. Sells 40,376 Shares of Merck & Co., Inc. $MRK
September 2 at 5:12 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-northwestern-mutual-wealth-management-co-sells-40376-shares-of-merck-co-inc-mrk-2026-09-02/
Did Merck’s (MRK) First Positive Phase 3 Individualized mRNA Cancer Trial Just Redefine Its Moat?
September 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/did-merck-mrk-first-positive-001902637.html
Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough
September 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/healthcare-etfs-watch-post-merck-142700952.html
The Oral PCSK9 Inhibitor Market Enters High-Growth Phase Owing to the Approval of Merck's LIPFENDRA and the Emergence of Oral PCSK9 Inhibitor Drugs, Including, AstraZeneca's AZD0780, Aqur's AQR-008, and Others | DelveInsight
September 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/oral-pcsk9-inhibitor-market-enters-143100912.html
Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough
September 1, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2983233/healthcare-etfs-to-watch-post-merck-moderna-cancer-vaccine-breakthrough?cid=cs-stocknewsapi-ft-etf_news_and_commentary-2983233

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cidara Therapeutics stock logo

Cidara Therapeutics NASDAQ:CDTX

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$150.37 -1.97 (-1.29%)
As of 09/4/2026 03:58 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas